ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0066

Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database

Emily Smitherman1, Rouba Chahine1, Aimee Hersh2 and Jeffrey Curtis3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Utah, Salt Lake City, UT, 3University of Alabama at Birmingham, Hoover, AL

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Health Services Research, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Data is lacking regarding modern real-world practices and disease outcomes of individuals with childhood-onset systemic lupus erythematosus (cSLE) and lupus nephritis, especially across multiple centers. However, researchers also lack approaches to identify end-stage kidney disease (ESKD) in patients with cSLE utilizing claims-based algorithms. Our objective was to determine optimal definitions that can be used to identify patients with cSLE, lupus nephritis, and ESKD using a large, real-world administrative claims database.

Methods: We utilized administrative claims data from IBM MarketScan Commercial and 8-State Medicaid Databases from 2006-2020. We adapted previously validated definitions to identify patients with cSLE: 1) ≥ 3 ambulatory or inpatient claims with ICD-9 code 710.0 or ICD-10-CM code M32.* (excluding M32.0 for drug-induced lupus) with at least 30 days between each code; 2) codes restricted to provider type pediatric rheumatology, rheumatology, pediatric nephrology, nephrology, dermatology, or acute care hospital; and 3) age ≥ 5 and < 18 years at the time of the first SLE code. To define incident diagnoses, we selected patients with: 1) at least 182 days between insurance enrollment and the first SLE code; and 2) no evidence of prior anti-malarial or immunosuppressive use more than 182 days before the first SLE code (Figure 1). We then adapted previously validated definitions to select the subgroup of cSLE patients with evidence of lupus nephritis using ≥ 2 ambulatory or inpatient claims with ICD-9 codes 580.*-586.*, 791.0 or ICD-10-CM codes M32.14, M32.15 with at least 30 days between each code. Finally, we defined presence of ESKD using: 1) procedure and diagnosis codes for dialysis from any encounter; 2) procedure and diagnosis codes for kidney transplant from any encounter; or 3) ≥ 3 claims with diagnosis codes for ESKD from any encounter type. We considered each ESKD criteria separately and as a composite if any of the 3 criteria were met. We calculated the frequency of patients meeting each of these criteria.

Results: From 2006-2020, we identified 2,590 individuals receiving care for cSLE in the IBM MarketScan Commercial and 8-State Medicaid Databases, of which 1,302 met criteria for an incident diagnosis. Definition for lupus nephritis was met in 580 (45%) of incident cSLE cases. Of individuals meeting the lupus nephritis definition, 166 (29%) had evidence of ESKD: 100 (17%) with dialysis, 83 (14%) with kidney transplant, and 69 (12%) with other ESKD diagnosis codes. Only 35 (4%) of 722 individuals with incident cSLE who did not meet lupus nephritis definition had evidence of ESKD: 24 (3%) with dialysis, 9 (1%) with kidney transplant, and 2 (0.3%) with other ESKD diagnosis codes (Table 1).

Conclusion: This study of individuals with evidence of cSLE and lupus nephritis within a US administrative claims database revealed a relatively high frequency of meeting ESKD criteria among cSLE patients. We identified few individuals with evidence of ESKD who did not meet previously validated lupus nephritis definitions; nevertheless, ESKD care should be included in the definition of lupus nephritis when using administrative claims algorithms.

Supporting image 1

Figure 1. Criteria used to select incident cases of childhood-onset systemic lupus erythematosus.

Supporting image 2

Table 1. Frequency of individuals meeting lupus nephritis and ESKD criteria out of the total number of defined incident cSLE cases within IBM MarketScan Commercial and 8-State Medicaid Databases from 2006_2020 (n=1,302).


Disclosures: E. Smitherman, None; R. Chahine, None; A. Hersh, None; J. Curtis, AbbVie/Abbott, Amgen, ArthritisPower, Aqtual, Bendcare, Bristol-Myers Squibb(BMS), CorEvitas, FASTER, GlaxoSmithKlein(GSK), IlluminationHealth, Janssen, Labcorp, Eli Lilly, Myriad, Novartis, Pfizer, Sanofi, Scipher, Setpoint, UCB, United Rheumatology.

To cite this abstract in AMA style:

Smitherman E, Chahine R, Hersh A, Curtis J. Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identifying-childhood-onset-systemic-lupus-erythematosus-lupus-nephritis-and-end-stage-kidney-disease-definitions-within-an-administrative-claims-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identifying-childhood-onset-systemic-lupus-erythematosus-lupus-nephritis-and-end-stage-kidney-disease-definitions-within-an-administrative-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology